ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO830

Elevated Levels of Soluble ST2 but Not Galectin-3 Are Associated with Increased Risk of Mortality in Patients with Hemodialysis

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Kim, Ae jin, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
  • Chun, Kayeong, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
  • Ro, Han, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
  • Chang, Jae Hyun, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
  • Lee, Hyun Hee, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
  • Chung, Wookyung, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
  • Jung, Ji Yong, Gachon University Gil Medical Center, College of Medicine, Gachon University, Incheon, Korea (the Republic of)
Background

Soluble ST2 (sST2) and galectin-3 has been proposed as novel biomarkers of cardiac fibrosis and heart failure, and may also predict cardiovascular event and mortality. However, there are limited data on the association between sST2 and galectin-3 and clinical outcomes in patients with end-stage renal disease. To determine this, we examined associations of sST2 and galectin-3 with all-cause mortality and cardiovascular events in patients with hemodialysis (HD)

Methods

This study included maintenance HD patients 18 years or older who consent to preserve their serum to the Bio Bank at our institution between March 2014 and March 2015. The primary outcome was all-cause mortality. The secondary outcome was composite of the cardiovascular event (CVE) and mortality. We used Cox proportional hazards regression analysis to evaluate associations between sST2 and galectin-3 levels and clinical outcomes. Patients were followed for CVE and mortality through March 2018.

Results

A total of 296 patients were analyzed in this study. Mean age was 57 ± 13 years, 52.9% were male. The mean serum level of sST2 was 24.81 ± 12.43 ng/ml and mean serum level of galectin-3 was 35.50 ± 9.91 ng/ml. Serum sST2 concentration was significantly associated with higher mortality (hazard ratio [HR], 1.043; 95% confidence interval [CI], 1.017 – 1.070; P = 0.001) and composite outcome including CVE and mortality (HR, 1.022; 95% CI, 1.003 – 1.040; P = 0.022) after adjustment for confounding factors. However, serum galectin-3 level was not independently associated with mortality nor composite outcome after adjustment.

Conclusion

Elevated levels of sST2 is independently associated with increased risk of adverse clinical outcomes in patients with HD.